ZYVOX I. V. Injection, ZYVOX Tablets, and ZYVOX for Oral Suspension contain linezolid, which is a synthetic antibacterial agent of the oxazolidinone class.
ZYVOX formulations are indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see
PRECAUTIONS, Pediatric Use
DOSAGE AND ADMINISTRATION
CLINICAL STUDIES). Linezolid is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected (see
infections, including cases with concurrent bacteremia (see
Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), or Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP]).
Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae. ZYVOX has not been studied in the treatment of decubitus ulcers.
Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes.
Community-acquired pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP] 1), including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible strains only).
To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Media Articles Related to Zyvox (Linezolid)
Zyvox® shows cost savings for treatment of skin infections
Source: The Doctors Lounge - Infections
Oral Zyvox® shows cost savings for outpatient treatment of skin and other infections when compared to vancomycin.
Published Studies Related to Zyvox (Linezolid)
Health economic evaluation of patients treated for nosocomial pneumonia caused by
methicillin-resistant Staphylococcus aureus: secondary analysis of a multicenter
randomized clinical trial of vancomycin and linezolid. 
PURPOSE: Results from studies comparing health care resource use (HCRU), costs of
treatment, and cost-effectiveness of linezolid compared with vancomycin therapy
in the treatment of hospitalized patients with methicillin-resistant
Staphylococcus aureus (MRSA) nosocomial pneumonia are limited in the published
Platelet profile in patients with acute bacterial skin and skin structure
infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH
clinical trials. 
Tedizolid, the active moiety of tedizolid phosphate, is a recently approved
oxazolidinone antibacterial with activity against a wide range of Gram-positive
pathogens, including resistant strains such as methicillin-resistant
Staphylococcus aureus. To date, 6 days of 200 mg tedizolid once daily has been
shown to be noninferior to 10 days of 600 mg linezolid twice daily in two
randomized, double-blind phase 3 trials (ESTABLISH-1 and ESTABLISH-2) for the
treatment of patients with acute bacterial skin and skin structure infections
Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a
randomized, controlled study. 
vancomycin regimen, for treatment of MRSA nosocomial pneumonia... CONCLUSIONS: For the treatment of MRSA nosocomial pneumonia, clinical response at
A randomised, double-blind trial comparing ceftobiprole medocaril with
ceftriaxone with or without linezolid for the treatment of patients with
community-acquired pneumonia requiring hospitalisation. 
Community-acquired pneumonia (CAP) is a serious infection requiring
hospitalisation in 20% of cases. The novel cephalosporin ceftobiprole has
microbiological activity against the major bacterial pathogens causing CAP,
including Streptococcus pneumoniae, Haemophilus influenzae and Klebsiella
pneumoniae, as well as against Staphylococcus aureus, including
Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of Phase III and IV randomized clinical trial data. [2011.12.02]
Objectives and methodsThe present study's objective was to evaluate serotonin toxicity with concomitant use of linezolid or comparators and serotonergic agents from 20 Phase III and IV comparator-controlled clinical studies on treatment of various Gram-positive infections.Based on the large database of Phase III and IV studies included in our analysis, we did not find enough evidence to conclude that linezolid-induced serotonin toxicity was different from that of comparators.
Clinical Trials Related to Zyvox (Linezolid)
A Study To Assess The Effect Of Linezolid On QTc Interval [Completed]
The FDA has asked Pfizer to assess the risk of linezolid on QT interval (obtained from ECG
readings) which could predispose patients to ventricular arrhythmias. This study is
conducted to satisfy this requirement.
Zyvox (Linezolid) Special Investigation For Vancomycin-Resistant Enterococci (VRE) [Completed]
To collect the efficacy and safety information in subjects who have been treated with Zyvox
(linezolid) for vancomycin resistance Enterococcus faecium infection for their appropriate
use in daily practice.
Drug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan) [Completed]
Drug use investigation of Zyvox for patients with Methicillin-resistant Staphylococcus
aureus (MRSA) infection disease.
The objective of this surveillance is to collect information about 1) adverse drug reaction
not expected from the Package Insert (unknown adverse drug reaction), 2) the incidence of
adverse drug reactions in this surveillance, and 3)factors considered to affect the safety
and/or efficacy of this drug.
Bioequivalence Study Comparing Linezolid 600 Mg Oral Suspension With 600 Mg Tablet In Chinese Healthy Male Subjects [Completed]
The purpose of this study is to estimate the bioequivalence comparing Linezolid 600 MG Oral
Suspension with 600 MG tablet in Chinese healthy male subjects. This study data will be used
to support Linezolid OS NDA in China.
Linezolid to Treat Extensively-Drug Resistant Tuberculosis [Active, not recruiting]
This study, conducted in Masan and Seoul, South Korea, investigated the effectiveness of
linezolid (LZD) in treating patients with extensively drug resistant tuberculosis (XDR TB).
Because regular medicines do not work well against XDR TB, many more people die from it than
from regular TB, which can be successfully treated by taking TB medication for 6 months.
Linezolid has been used to treat other kinds of infections, but has not been well studied
for TB. This study examined the side effects and effectiveness of prolonged treatment with
linezolid at two different doses.
People 20 years of age and older who have XDR TB were eligible for this 3-year study.
Participants underwent the following tests and procedures:
- LZD treatment: Patients were randomly assigned to one of two study groups. Group 1
patients were observed for 2 months before starting LZD, while group 2 patients begin
taking LZD right away. Both groups began with a 600 mg daily dose of LZD. After
patients stopped coughing up TB germs (or after 4 months on LZD) they were randomly
assigned either to continue taking 600 mg of LZD for the rest of the study or to take a
decreased dose of 300 mg. In addition to LZD, patients continued to take their
currently prescribed TB medications.
- Medical history.
- Physical examinations each month during treatment.
- Sputum collections once a week or more until 3 weeks after the patient was no longer
- Blood draws every week for 16 to 24 weeks and then once a month.
- Urine collections at several time points.
- Nerve and eye examinations before starting treatment and then monthly to look for
possible LZD side effects.
- CT scans of the lungs three to four times the first year and once more later in the
study. For this test the patient lay on a table within the doughnut-shaped CT scanner
while special X-ray pictures are taken.
Patients who participated in a substudy had PET scans instead of the CT scans. For this
test, the patient was given an injection into a vein of a radioactive chemical that can be
detected by a special camera and viewed on a screen. The patient lay on a table within the
doughnut-shaped scanner while pictures were taken.
Reports of Suspected Zyvox (Linezolid) Side Effects
Drug Interaction (31),
Platelet Count Decreased (29),
Renal Failure Acute (25),
Serotonin Syndrome (23), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Zyvox has an overall score of 9. The effectiveness score is 10 and the side effect score is 6. The scores are on ten point scale: 10 - best, 1 - worst.
Zyvox review by 48 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || Moderate Side Effects|
|Condition / reason:|| || MRSA|
|Dosage & duration:|| || 600 mg taken twice a day for the period of 10 days|
|Other conditions:|| || none|
|Other drugs taken:|| || none|
|Benefits:|| || It cured the MRSA. Major downside was high price. The resulting yeast infection was a bit irritating but not unexpected.I would highly recmmend zyvox to anyone with this particular strain of MRSA.|
|Side effects:|| || Yeast infection and minor queasiness.|
|Comments:|| || Pill form, 2 a day. It was pretty simple. I had been receiving it in the hospital as a drip (liquid).|
Page last updated: 2015-08-10